- Home
- NMIH vs AMLX Comparison
NMIH vs AMLX Comparison
Compare NMIH & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | AMLX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NMIH | AMLX |
|---|---|---|
| Price | $42.11 | $28.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $48.88 | $43.00 |
| AVG Volume (30 Days) | 767.8K | ★ 1.3M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.06 | ★ 65.46 |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $706,440,000.00 | $380,786,000.00 |
| Revenue This Year | $6.63 | N/A |
| Revenue Next Year | $5.40 | N/A |
| P/E Ratio | $15.98 | ★ N/A |
| Revenue Growth | 8.52 | ★ 1612.94 |
| 52 Week Low | $34.84 | $10.83 |
| 52 Week High | $46.74 | $41.14 |
Technical Indicators
Market Signals| Indicator | NMIH | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 48.57 |
| Support Level | $40.97 | $26.12 |
| Resistance Level | $43.36 | $28.60 |
| Average True Range (ATR) | 1.01 | 1.31 |
| MACD | 0.40 | 0.17 |
| Stochastic Oscillator | 72.19 | 54.21 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.